GEP20063909B - 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES - Google Patents

2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES

Info

Publication number
GEP20063909B
GEP20063909B GE5674A GEAP2003005674A GEP20063909B GE P20063909 B GEP20063909 B GE P20063909B GE 5674 A GE5674 A GE 5674A GE AP2003005674 A GEAP2003005674 A GE AP2003005674A GE P20063909 B GEP20063909 B GE P20063909B
Authority
GE
Georgia
Prior art keywords
pyrido
ylamino
pyrimidin
pyridin
ones
Prior art date
Application number
GE5674A
Other languages
English (en)
Inventor
Mark Robert Barvian
Richard John Booth
John Quin Iii
Joseph Thomas Repine
Derek James Sheehan
Peter Laurence Toogood
Scott Norman Vanderwel
Hairong Zhou
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27613435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20063909(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of GEP20063909B publication Critical patent/GEP20063909B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
GE5674A 2002-01-22 2003-01-10 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES GEP20063909B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35087702P 2002-01-22 2002-01-22

Publications (1)

Publication Number Publication Date
GEP20063909B true GEP20063909B (en) 2006-08-25

Family

ID=27613435

Family Applications (1)

Application Number Title Priority Date Filing Date
GE5674A GEP20063909B (en) 2002-01-22 2003-01-10 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES

Country Status (52)

Country Link
US (4) US6936612B2 (enExample)
EP (1) EP1470124B1 (enExample)
JP (1) JP4291696B2 (enExample)
KR (2) KR100669578B1 (enExample)
CN (3) CN101001857B (enExample)
AP (1) AP1767A (enExample)
AR (2) AR038814A1 (enExample)
AT (1) ATE314370T1 (enExample)
AU (1) AU2003237009B2 (enExample)
BE (1) BE2017C005I2 (enExample)
BR (2) BRPI0307057B8 (enExample)
CA (1) CA2473026C (enExample)
CO (1) CO5700765A2 (enExample)
CR (1) CR20120129A (enExample)
CY (2) CY1105686T1 (enExample)
DE (1) DE60303009T2 (enExample)
DK (1) DK1470124T3 (enExample)
DO (1) DOP2003000561A (enExample)
EA (1) EA007395B3 (enExample)
EC (2) ECSP045201A (enExample)
ES (1) ES2251677T3 (enExample)
FR (1) FR17C1012I2 (enExample)
GE (1) GEP20063909B (enExample)
GT (1) GT200300005A (enExample)
HN (1) HN2003000039A (enExample)
HR (1) HRP20040660B1 (enExample)
HU (2) HUS1700009I1 (enExample)
IL (3) IL162721A0 (enExample)
IS (1) IS2423B (enExample)
LT (1) LTC1470124I2 (enExample)
LU (1) LUC00009I2 (enExample)
MA (1) MA27166A1 (enExample)
ME (1) ME00230B (enExample)
MX (1) MXPA04005939A (enExample)
MY (1) MY134818A (enExample)
NI (1) NI200300008A (enExample)
NL (1) NL300863I2 (enExample)
NO (2) NO329350B1 (enExample)
NZ (1) NZ534069A (enExample)
OA (1) OA12755A (enExample)
PA (1) PA8563701A1 (enExample)
PE (1) PE20030975A1 (enExample)
PL (2) PL218692B1 (enExample)
RS (1) RS51044B (enExample)
SI (1) SI1470124T1 (enExample)
SV (1) SV2004001459A (enExample)
TN (1) TNSN04126A1 (enExample)
TW (1) TWI343920B (enExample)
UA (1) UA79444C2 (enExample)
UY (1) UY27617A1 (enExample)
WO (1) WO2003062236A1 (enExample)
ZA (1) ZA200404840B (enExample)

Families Citing this family (326)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
AU2001278908A1 (en) * 2000-08-04 2002-02-18 Warner Lambert Company Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido(2,3-d)pyrimidin 7-ones
JP2005507392A (ja) * 2000-08-04 2005-03-17 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ２−（４−ピリジル）アミノ−６−ジアルキルオキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン類の製造方法
CN100376571C (zh) * 2001-02-12 2008-03-26 霍夫曼-拉罗奇有限公司 6-取代的吡啶并嘧啶类化合物
EP1364950A4 (en) * 2001-02-26 2005-03-09 Tanabe Seiyaku Co Pyridopyrimidine and naphthyridine derivatives
WO2003000270A1 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidones and uses thereof
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
ES2251677T3 (es) 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
CA2492112A1 (en) 2002-08-06 2004-02-19 F. Hoffmann-La Roche Ag 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
US7129351B2 (en) 2002-11-04 2006-10-31 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
WO2004052862A1 (ja) * 2002-12-10 2004-06-24 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
KR20050111636A (ko) 2003-04-10 2005-11-25 에프. 호프만-라 로슈 아게 피리미도 화합물
ATE412650T1 (de) * 2003-07-11 2008-11-15 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
BRPI0412259B1 (pt) 2003-07-22 2019-08-20 Astex Therapeutics Limited Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica
WO2005011654A2 (en) * 2003-07-29 2005-02-10 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
JP4616839B2 (ja) * 2003-11-13 2011-01-19 エフ．ホフマン−ラ ロシュ アーゲー ヒドロキシアルキル置換ピリド−７−ピリミジン−７−オン類
WO2005058341A2 (en) * 2003-12-11 2005-06-30 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
DK1713806T3 (da) * 2004-02-14 2013-08-05 Irm Llc Forbindelser og sammensætninger som proteinkinaseinhibitorer
BRPI0507852A (pt) * 2004-02-18 2007-07-10 Warner Lambert Co 2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
SI1761528T1 (sl) * 2004-06-11 2008-06-30 Japan Tobacco Inc 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka
WO2006053043A2 (en) 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
JP5475234B2 (ja) * 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
JP2008528469A (ja) * 2005-01-21 2008-07-31 アステックス・セラピューティクス・リミテッド ピラゾールキナーゼ阻害剤およびさらなる抗癌剤の組合せ剤
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AU2006207325B2 (en) * 2005-01-21 2012-08-16 Astex Therapeutics Limited Pharmaceutical compounds
WO2006090853A1 (ja) 2005-02-25 2006-08-31 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
PE20061193A1 (es) * 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
UY29440A1 (es) * 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
BR122020016659B8 (pt) 2005-05-10 2021-07-27 Incyte Holdings Corp moduladores de 2,3-dioxigenase de indolamina e métodos de modulação de atividade de inibição e de imunossupressão
KR100734837B1 (ko) * 2005-09-16 2007-07-03 한국전자통신연구원 다중 생체 인식 시스템 및 그 방법
EP1931667A1 (en) * 2005-09-28 2008-06-18 Ranbaxy Laboratories Limited Pyrido-pyridimidine derivatives useful as antiinflammatory agents
BRPI0617159B8 (pt) * 2005-10-07 2021-05-25 Exelixis Inc compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
EP2026805A1 (en) * 2006-05-08 2009-02-25 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
EP2032134B1 (en) 2006-05-09 2015-06-24 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
RU2009108006A (ru) * 2006-09-08 2010-10-20 Пфайзер Продактс Инк. (Us) Синтез 2-(пиридин-2-иламино)-пиридо[2, 3-d]пиримидин-7-онов
WO2008032162A1 (en) 2006-09-15 2008-03-20 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
WO2008150260A1 (en) * 2007-06-06 2008-12-11 Gpc Biotech, Inc. 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
AU2007311480A1 (en) * 2006-10-16 2008-04-24 Forma Therapeutics, Inc. Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
CA2668731A1 (en) * 2006-11-09 2008-05-15 Tobias Gabriel Kinase inhibitors and methods for using the same
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
AU2008307516B2 (en) 2007-10-05 2011-11-17 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
ATE531372T1 (de) 2008-04-07 2011-11-15 Amgen Inc Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
BR122019015876B8 (pt) 2008-07-08 2021-07-27 Incyte Holdings Corp compostos derivados de 1,2,5-oxadiazóis, composição, bem como seus usos
WO2010014554A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
PL2331547T3 (pl) * 2008-08-22 2015-01-30 Novartis Ag Związki pirolopirymidynowe jako inhibitory CDK
AU2009310352A1 (en) 2008-10-01 2010-05-06 The University Of North Carolina At Chapel Hill Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
CN102231984A (zh) * 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护
KR101687039B1 (ko) 2008-10-03 2016-12-15 젠자임 코포레이션 2-아실아미노프로판올형 글루코실세라미드 합성효소 억제제
PA8852901A1 (es) * 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
BRPI1008709B8 (pt) 2009-04-03 2021-05-25 Hoffmann La Roche dispersão sólida, formulação, composição e comprimido compreendendo {3-[5-(4-cloro-fenil)-1h-pirrol[2,3-b]piridina-3-carbonil]-2,4-diflúor-fenil}-amida do ácido propano-1-sulfônico
EP3025724B1 (en) * 2009-05-13 2018-07-11 The University of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
US20120245344A1 (en) * 2009-08-31 2012-09-27 Nippon Chemiphar Co., Ltd. Gpr119 agonist
WO2011044535A2 (en) * 2009-10-09 2011-04-14 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
US20110112127A1 (en) 2009-11-06 2011-05-12 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
KR101754664B1 (ko) 2009-12-18 2017-07-06 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 치환된 피리도〔2,3-ｄ〕피리미딘-7(8ｈ)-온스 및 이의 치료 용도
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
CA2800327A1 (en) * 2010-04-13 2011-10-20 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
US8680099B2 (en) * 2010-06-10 2014-03-25 Afraxis Holdings, Inc. 6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
EP2580320B1 (en) 2010-06-14 2018-08-01 The Scripps Research Institute Reprogramming of cells to a new fate
BR112013002375B1 (pt) 2010-08-05 2020-05-12 Temple University - Of The Commonwealth System Of Higher Education Composto, processo de preparação do mesmo, composição farmacêutica, e, usos de um composto
PL2632467T3 (pl) 2010-10-25 2016-12-30 Inhibitory CDK
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
WO2012068381A2 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
MY162950A (en) 2011-02-07 2017-07-31 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
MX2013010871A (es) 2011-03-23 2014-01-31 Amgen Inc Inhibidores dobles triciclicos fusionados de cdk 4/6 y flt3.
WO2012166586A1 (en) 2011-05-27 2012-12-06 Temple University - Of The Commonwealth System Of Higher Education SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF
EA029768B1 (ru) * 2012-03-14 2018-05-31 Люпин Лимитед Гетероциклильные соединения
CA2868966C (en) 2012-03-29 2021-01-26 Francis Xavier Tavares Lactam kinase inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
HUE055502T2 (hu) 2012-07-11 2021-11-29 Blueprint Medicines Corp Fibroblaszt növekedési faktor receptor gátlók
EP2880448B1 (en) 2012-08-03 2022-06-29 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
EP2885303B1 (en) 2012-08-17 2018-12-26 CoNCERT Pharmaceuticals, Inc. Deuterated baricitinib
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
TR201816077T4 (tr) 2013-02-21 2018-11-21 Pfizer Seçici bir cdk4/6 inhibitörünün katı formları.
MX2015012741A (es) 2013-03-15 2016-02-19 Concert Pharmaceuticals Inc Palbociclib deuterado.
WO2014144740A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
WO2014144326A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
CN104470921B (zh) * 2013-05-17 2017-05-03 上海恒瑞医药有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
CA2928042C (en) 2013-10-25 2022-05-10 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2015095840A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of cdk and erk inhibitors
US9949976B2 (en) 2013-12-31 2018-04-24 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
CA2935103C (en) 2013-12-31 2018-08-28 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2015161283A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
DK3148532T3 (en) 2014-05-28 2021-04-26 Piramal Entpr Ltd Pharmaceutical Combination Comprising a CDK Inhibitor and a Thioredoxin Reductase Inhibitor for the Treatment of Cancer
CN110117273B (zh) 2014-07-24 2022-02-01 贝达医药公司 作为细胞周期蛋白依赖性激酶(cdk)抑制剂的2h-吲唑衍生物及其医疗用途
US9828373B2 (en) 2014-07-26 2017-11-28 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
WO2016016769A1 (en) * 2014-07-31 2016-02-04 Sun Pharmaceutical Industries Limited A process for the preparation of palbociclib
TW201618773A (zh) * 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
EP3180007A1 (en) * 2014-08-14 2017-06-21 Sun Pharmaceutical Industries Ltd Crystalline forms of palbociclib
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
CN105111201B (zh) * 2014-10-16 2017-01-11 上海页岩科技有限公司 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016066420A1 (en) * 2014-10-29 2016-05-06 Sandoz Ag Crystalline forms of palbociclib monohydrochloride
CN105622638B (zh) * 2014-10-29 2018-10-02 广州必贝特医药技术有限公司 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
CN105616418A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
ES2941897T3 (es) 2014-11-12 2023-05-26 Seagen Inc Compuestos que interaccionan con glicanos y procedimientos de uso
CN104496983B (zh) 2014-11-26 2016-06-08 苏州明锐医药科技有限公司 一种帕博西尼的制备方法
CN104447743B (zh) * 2014-11-26 2016-03-02 苏州明锐医药科技有限公司 帕博西尼的制备方法
WO2016090257A1 (en) * 2014-12-05 2016-06-09 Crystal Pharmatech Inc. Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
WO2016092442A1 (en) * 2014-12-08 2016-06-16 Sun Pharmaceutical Industries Limited Processes for the preparation of crystalline forms of palbociclib acetate
WO2016107605A1 (zh) 2014-12-31 2016-07-07 昆明积大制药股份有限公司 药物组合物及其制备方法
CN105732615B (zh) * 2014-12-31 2018-05-01 山东轩竹医药科技有限公司 Cdk激酶抑制剂
CN104610254B (zh) * 2015-01-26 2017-02-01 新发药业有限公司 一种帕博赛布的低成本制备方法
CZ201589A3 (cs) 2015-02-11 2016-08-24 Zentiva, K.S. Pevné formy soli Palbociclibu
TWI690533B (zh) 2015-02-12 2020-04-11 南北兄弟藥業投資有限公司 Ｃｄｋ類小分子抑制劑的化合物及其用途
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
EP3078663A1 (en) 2015-04-09 2016-10-12 Sandoz Ag Modified particles of palbociclib
WO2016156070A1 (en) 2015-04-02 2016-10-06 Sandoz Ag Modified particles of palbociclib
CN106795159B (zh) * 2015-04-22 2018-12-28 江苏恒瑞医药股份有限公司 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法
TWI696617B (zh) * 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑
PT3305785T (pt) 2015-05-29 2021-10-13 Teijin Pharma Ltd Derivado de pirido[3,4-d]pirimidina e seu sal farmaceuticamente aceitável
CR20170540A (es) 2015-06-04 2018-02-02 Pfizer Formas de dosificación solidas de palbociclib
CN104892604B (zh) * 2015-06-19 2016-08-24 北京康立生医药技术开发有限公司 一种cdk4抑制剂的合成方法
CN106699785A (zh) * 2015-07-13 2017-05-24 南开大学 作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
ES2741958T3 (es) 2015-08-05 2020-02-12 Ratiopharm Gmbh Nueva forma cristalina y aductos de ácido acético de palbociclib
CN105085517B (zh) * 2015-08-06 2016-11-23 天津华洛康生物科技有限公司 一种结晶型帕博西尼游离碱水合物及其制备方法
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
HU230962B1 (hu) 2015-10-28 2019-06-28 Egis Gyógyszergyár Zrt. Palbociclib sók
CN106632311B (zh) * 2015-11-02 2021-05-18 上海科胜药物研发有限公司 一种帕博西尼晶型a和晶型b的制备方法
SG11201803213XA (en) 2015-11-12 2018-05-30 Siamab Therapeutics Inc Glycan-interacting compounds and methods of use
CN105418603A (zh) * 2015-11-17 2016-03-23 重庆莱美药业股份有限公司 一种高纯度帕布昔利布及其反应中间体的制备方法
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
JP6951767B2 (ja) * 2015-12-13 2021-10-20 ハンジョウ イノゲート ファーマ カンパニー リミテッドＨａｎｇｚｈｏｕ Ｉｎｎｏｇａｔｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 抗癌薬として使用される複素環式化合物
CN105418609B (zh) * 2015-12-31 2017-06-23 山东大学 4‑(1,2,3‑三氮唑取代苯胺基)‑吡啶骈嘧啶酮衍生物及其制备方法与应用
US10662186B2 (en) 2015-12-31 2020-05-26 Shanghai Pharmaceuticals Holding Co., Ltd. Substituted pyrimidines as cyclin-dependent kinase inhibitors
CN106967061A (zh) * 2016-01-13 2017-07-21 常州方楠医药技术有限公司 帕博西林的盐、晶型及其制备方法
WO2017130219A1 (en) 2016-01-25 2017-08-03 Mylan Laboratories Limited Amorphous solid dispersion of palbociclib
WO2017145054A1 (en) 2016-02-24 2017-08-31 Lupin Limited Modified particles of crystalline palbociclib free base and process for the preparation thereof
US11077110B2 (en) 2016-03-18 2021-08-03 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN107266421B (zh) * 2016-04-08 2020-12-04 正大天晴药业集团股份有限公司 取代的苯并咪唑类衍生物
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
WO2017185031A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
CN106336411B (zh) * 2016-04-27 2018-03-06 上海医药集团股份有限公司 Cdk4/6抑制剂帕博西尼高纯度原料药的制备工艺及用途
CN105949189B (zh) * 2016-06-05 2017-09-22 童明琼 一种用于治疗乳腺癌的帕博西尼的制备方法
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
CA3028751A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
WO2018007927A1 (en) 2016-07-04 2018-01-11 Dr. Reddy's Laboratories Limited Process for preparation of palbociclib
EP3481825A1 (en) 2016-07-07 2019-05-15 Plantex Ltd. Solid state forms of palbociclib dimesylate
MY198534A (en) 2016-08-15 2023-09-04 Pfizer Pyridopyrimdinone cdk2/4/6 inhibitors
JP7190425B2 (ja) 2016-08-23 2022-12-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌の治療のための併用療法
US20190192522A1 (en) 2016-09-08 2019-06-27 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors
WO2018065999A1 (en) 2016-10-07 2018-04-12 Mylan Laboratories Limited Novel polymorph of an intermediate for palbociclib synthesis
WO2018073574A1 (en) 2016-10-20 2018-04-26 Cipla Limited Polymorphic forms of palbociclib
MX2019004602A (es) 2016-10-20 2019-06-17 Pfizer Agentes anti-proliferativos para tratar pah.
CN106565707B (zh) * 2016-11-03 2019-01-04 杭州科巢生物科技有限公司 帕博西尼新合成方法
US11865176B2 (en) 2016-11-08 2024-01-09 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
US20190275049A1 (en) 2016-11-16 2019-09-12 Pfizer Inc. Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
SI3546458T1 (sl) 2016-11-28 2021-03-31 Teijin Pharma Limited Derivati ((piridin-2-il)-amino)pirido(3,4-d)pirimidina in ((piridazin-3-il)amino)pirido(3,4-d)pirimidina kot zaviralci CDK4/6 za zdravljenje npr. revmatoidnega artritisa, arterioskleroze, pljučne fibroze, možganske kapi ali raka
CN109996800B (zh) 2016-11-28 2021-11-19 帝人制药株式会社 吡啶并[3,4-d]嘧啶衍生物或其溶剂合物的晶体
TWI749126B (zh) 2016-12-16 2021-12-11 大陸商基石藥業（蘇州）有限公司 Cdk4/6抑制劑
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
CN108191857B (zh) * 2017-01-24 2020-10-23 晟科药业（江苏）有限公司 6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂
US10729692B2 (en) * 2017-02-26 2020-08-04 Institute For Cancer Research Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
MX2019010202A (es) 2017-03-03 2019-10-02 Seattle Genetics Inc Compuestos que interactuan con glicano y metodos de uso.
CN110809576B (zh) * 2017-03-03 2022-08-30 奥克兰联合服务有限公司 Fgfr激酶抑制剂和药物用途
KR102517650B1 (ko) 2017-03-16 2023-04-05 에자이 알앤드디 매니지먼트 가부시키가이샤 유방암의 치료를 위한 조합물 요법
CN108658854A (zh) * 2017-03-28 2018-10-16 中国海洋大学 一种生物碱化合物及其制备方法和作为海洋防污剂的应用
CN108658855A (zh) * 2017-03-28 2018-10-16 中国海洋大学 一种含氮双环化合物及其制备方法和用途
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
BR112019026483A2 (pt) 2017-06-16 2020-07-14 Beta Pharma, Inc. formulação farmacêutica de n-(2-(2-(dimetilamina)etoxi)-4-metoxi-5-((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amina)fenil)acrilamida e seus sais
MX392531B (es) 2017-06-29 2025-03-24 G1 Therapeutics Inc Formas morficas de g1t38 y metodos de preparacion de las mismas.
EA036060B1 (ru) * 2017-07-17 2020-09-21 Пфайзер Инк. Пиридопиримидиноновые ингибиторы cdk2/4/6
US11529353B2 (en) 2017-07-28 2022-12-20 Synthon B.V. Pharmaceutical composition comprising Palbociclib
CN109384767B (zh) * 2017-08-08 2020-05-05 江苏恒瑞医药股份有限公司 一种吡啶并嘧啶类衍生物的制备方法及其中间体
EP3676404B1 (en) 2017-08-31 2025-09-03 Novartis AG Methods of selecting a treatment for breast cancer patients
CN107488175A (zh) * 2017-09-04 2017-12-19 上海微巨实业有限公司 一种帕博西林关键中间体的制备方法
WO2019070755A1 (en) 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
JP7569688B2 (ja) 2017-12-22 2024-10-18 ハイバーセル，インコーポレイテッド ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体
CN108586452A (zh) * 2018-01-12 2018-09-28 重庆市碚圣医药科技股份有限公司 一种帕博西尼中间体的合成方法
TW201940166A (zh) 2018-01-29 2019-10-16 美商貝達醫藥公司 作為cdk4及cdk6抑制劑之2h-吲唑衍生物及其治療用途
CN108218861B (zh) * 2018-02-05 2019-07-23 黑龙江中医药大学 一种预防和治疗糖尿病的药物及其制备方法
KR102765922B1 (ko) 2018-02-06 2025-02-11 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 선택적인 에스트로겐 수용체 분해제로서의 치환된 벤조티오펜 유사체
JP2021514975A (ja) 2018-02-27 2021-06-17 ファイザー・インク サイクリン依存性キナーゼ阻害剤およびｂｅｔ−ブロモドメイン阻害剤の組合せ
MX2020008949A (es) 2018-02-27 2021-01-08 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b.
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
PL3793609T3 (pl) 2018-05-14 2024-05-13 Pfizer Inc. Preparat w postaci doustnego roztworu
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
SI3802529T1 (sl) 2018-05-24 2024-03-29 Synthon B.V. Postopek za izdelavo palbocikliba
IL279829B2 (en) 2018-07-05 2025-05-01 Incyte Holdings Corp Fused pyrazine derivatives as A2A/A2B inhibitors
BR112021001233A2 (pt) 2018-07-23 2021-04-20 F. Hoffmann-La Roche Ag método para tratar câncer em um paciente, uso de uma quantidade terapeuticamente eficaz de gdc-0077 e quantidade terapeuticamente eficaz de gdc-0077
US12486280B2 (en) 2018-07-27 2025-12-02 California Institute Of Technology CDK inhibitors and uses thereof
CN112839657B (zh) 2018-08-24 2025-07-25 法码科思莫斯控股有限公司 1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成
JP6952747B2 (ja) 2018-09-18 2021-10-20 ファイザー・インク がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
WO2020076432A1 (en) 2018-10-08 2020-04-16 Genentech, Inc. Methods of treating cancer with pi3k alpha inhibitors and metformin
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
TW202035406A (zh) 2018-12-07 2020-10-01 大陸商杭州英創醫藥科技有限公司 作為cdk-hdac雙通路抑制劑的雜環化合物
KR20210107069A (ko) 2018-12-21 2021-08-31 다이이찌 산쿄 가부시키가이샤 항체-약물 컨쥬게이트와 키나아제 저해제의 조합
CA3124574A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
CA3124569A1 (en) 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020157709A1 (en) 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
PH12021551976A1 (en) * 2019-02-15 2022-07-04 Incyte Corp Cyclin-dependent kinase 2 biomarkers and uses thereof
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
CA3141452A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
US20220241412A1 (en) 2019-05-24 2022-08-04 Pfizer Inc. Combination therapies using cdk inhibitors
CN112010844B (zh) * 2019-05-31 2023-07-25 中国药科大学 N-(嘧啶-2-基)香豆素-7-胺衍生物作为蛋白激酶抑制剂的制法和应用
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN112094272A (zh) 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
WO2020253808A1 (zh) * 2019-06-20 2020-12-24 江苏恒瑞医药股份有限公司 一种药物组合物以及其制备方法
CN110143948B (zh) * 2019-06-21 2021-05-14 上海博悦生物科技有限公司 Cdk4/6抑制剂、其药物组合物、制备方法及应用
JP7616794B2 (ja) 2019-07-07 2025-01-17 オレマ ファーマシューティカルズ インク． エストロゲン受容体アンタゴニストのレジメン
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021022172A1 (en) 2019-08-01 2021-02-04 Incyte Corporation A dosing regimen for an ido inhibitor
CA3150681A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
MX2022002415A (es) 2019-08-26 2022-03-22 Arvinas Operations Inc Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021072232A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN112759589B (zh) * 2019-11-01 2022-04-08 暨南大学 嘧啶并吡啶酮类化合物及其应用
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
WO2021113219A1 (en) 2019-12-03 2021-06-10 Genentech, Inc. Combination therapies for treatment of breast cancer
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
MX2022007488A (es) * 2019-12-16 2022-08-02 Lunella Biotech Inc Agentes terapeuticos selectivos contra el cancer inhibidores de cdk4/6.
MX2022007487A (es) 2019-12-16 2022-08-04 Lunella Biotech Inc Agentes terapeuticos selectivos contra el cancer inhibidores de cdk4/6.
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12539304B2 (en) 2020-03-05 2026-02-03 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
EP4118082A4 (en) * 2020-03-13 2024-05-01 Prosenestar LLC PYRIDO[2,3-D PYRIMIDIN-7(8H)-ONE AS CDK INHIBITORS
WO2021190637A1 (en) * 2020-03-27 2021-09-30 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Combination of anti-her2 antibody and cdk inhibitior for tumor treatment
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
CN121270549A (zh) 2020-04-16 2026-01-06 因赛特公司 稠合三环kras抑制剂
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
AU2021273744A1 (en) 2020-05-19 2022-12-08 Pharmacosmos Holding A/S Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
EP4157847A4 (en) * 2020-05-28 2024-06-19 University of Washington Drug-like molecules and methods for the therapeutic targeting of viral rna structures
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
CN113880809B (zh) 2020-07-03 2022-10-18 盛世泰科生物医药技术(苏州)有限公司 一种嘧啶类衍生物及其制备方法和应用
EP4667055A2 (en) 2020-07-15 2025-12-24 Pfizer Inc. Kat6 inhibitor methods and combinations for cancer treatment
EP4181919A1 (en) 2020-07-20 2023-05-24 Pfizer Inc. Combination therapy
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
WO2022063119A1 (zh) * 2020-09-24 2022-03-31 南京济群医药科技股份有限公司 一种羟乙磺酸哌柏西利的组合物及药物
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
WO2022091001A1 (en) 2020-10-29 2022-05-05 Pfizer Ireland Pharmaceuticals Process for preparation of palbociclib
WO2022123419A1 (en) 2020-12-08 2022-06-16 Pfizer Inc. Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
CN112569361B (zh) * 2020-12-30 2023-01-10 扬子江药业集团上海海尼药业有限公司 一种哌柏西利干混悬组合物及其制备方法
WO2022155941A1 (en) 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
WO2022206888A1 (en) 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
EP4353724A4 (en) * 2021-06-09 2025-10-08 Tyk Medicines Zhengzhou Inc COMPOUND USEFUL AS A CYCLIN-DEPENDENT KINASE INHIBITOR AND USE THEREOF
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
IL309642A (en) 2021-07-07 2024-02-01 Incyte Corp Tricyclic compounds as inhibitors of Kras
JP2024529347A (ja) 2021-07-14 2024-08-06 インサイト・コーポレイション Ｋｒａｓの阻害剤としての三環式化合物
CA3217661A1 (en) 2021-07-16 2023-01-19 Alyssa VERANO Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
US12350276B2 (en) 2021-07-26 2025-07-08 Celcuity Inc. Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
US12441742B2 (en) 2021-08-31 2025-10-14 Incyte Corporation Naphthyridine compounds as inhibitors of KRAS
CN113683612B (zh) * 2021-09-07 2022-06-17 山东铂源药业股份有限公司 一种帕布昔利布的制备方法
WO2023040914A1 (zh) * 2021-09-14 2023-03-23 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
US12030884B2 (en) 2021-10-01 2024-07-09 Incyte Corporation Pyrazoloquinoline KRAS inhibitors
CA3235146A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
IL312886A (en) 2021-11-22 2024-07-01 Incyte Corp Combined treatment that includes a Pegfer inhibitor and a Kras inhibitor
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
IL313422A (en) 2021-12-10 2024-08-01 Lilly Co Eli CDK4 and 6 inhibitor in combination with FULVESTRANT for the treatment of advanced or metastatic breast cancer in patients with advanced or metastatic breast cancer before CDK 4 and 4
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2023111810A1 (en) 2021-12-14 2023-06-22 Pfizer Inc. Combination therapies and uses for treating cancer
WO2023114264A1 (en) 2021-12-15 2023-06-22 Eli Lilly And Company Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
JP2025500466A (ja) 2021-12-22 2025-01-09 インサイト・コーポレイション Ｆｇｆｒ阻害剤の塩及び固体の形態ならびにその調製方法
WO2023168686A1 (en) 2022-03-11 2023-09-14 Qilu Regor Therapeutics Inc. Substituted cyclopentanes as cdk2 inhibitors
TW202341982A (zh) 2021-12-24 2023-11-01 大陸商上海齊魯銳格醫藥研發有限公司 Ｃｄｋ２抑制劑及其用途
CN114456180B (zh) * 2022-02-18 2023-07-25 贵州大学 用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
TW202342023A (zh) 2022-03-07 2023-11-01 美商英塞特公司 Ｃｄｋ２抑制劑之固體形式、鹽及製備方法
HU231594B1 (hu) * 2022-05-10 2025-03-28 Egis Gyógyszergyár Zrt. Palbociclibet és letrozolt tartalmazó gyógyszerkészítmény
AR129675A1 (es) 2022-06-22 2024-09-18 Incyte Corp Inhibidores de cdk12 de aminas biciclicas
EP4302832A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing glucono delta lactone
EP4302755B1 (en) 2022-07-07 2025-08-20 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing an amino acid
WO2024015731A1 (en) 2022-07-11 2024-01-18 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
CN117430597A (zh) * 2022-07-14 2024-01-23 浙江同源康医药股份有限公司 用作cdk4激酶抑制剂的化合物及其应用
CN119604288A (zh) 2022-07-29 2025-03-11 辉瑞大药厂 用于治疗癌症的包含kat6抑制剂的给药方案
TW202539669A (zh) 2022-08-31 2025-10-16 美商亞文納營運公司 雌激素受體降解劑之給藥方案
CN120456897A (zh) 2022-11-02 2025-08-08 佩特拉制药公司 用于治疗疾病的磷酸肌醇3-激酶(pi3k)变构色原酮抑制剂
CN120187416A (zh) 2022-11-11 2025-06-20 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
TW202440571A (zh) * 2022-12-16 2024-10-16 大陸商上海岸闊醫藥科技有限公司 化合物及其用途
WO2024133726A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024132652A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024201334A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
WO2024220645A1 (en) 2023-04-18 2024-10-24 Incyte Corporation 2-azabicyclo[2.2.1]heptane kras inhibitors
US20240390340A1 (en) 2023-04-18 2024-11-28 Incyte Corporation Pyrrolidine kras inhibitors
WO2024231275A1 (en) 2023-05-05 2024-11-14 Astrazeneca Ab Combination of capivasertib, a cdk4/6 inhibitor and fulvestrant for use in the treatment of breast cancer
WO2024235844A1 (en) 2023-05-12 2024-11-21 Institut National de la Santé et de la Recherche Médicale Methods of preventing on-target genotoxicity induced by nucleases
WO2024254245A1 (en) 2023-06-09 2024-12-12 Incyte Corporation Bicyclic amines as cdk2 inhibitors
WO2025051337A1 (en) 2023-09-06 2025-03-13 Afyx Development A/S Compositions and methods for treating and preventing oral cancer
US20250163079A1 (en) 2023-11-01 2025-05-22 Incyte Corporation Kras inhibitors
TW202532065A (zh) 2023-12-04 2025-08-16 美商建南德克公司 治療乳癌之組合療法
WO2025129002A1 (en) 2023-12-13 2025-06-19 Incyte Corporation Bicyclooctane kras inhibitors
WO2025202854A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
WO2026025013A2 (en) 2024-07-26 2026-01-29 Pfizer Inc. Combination therapy using cdk4 inhibitors for cancer treatments

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5618982A (en) 1979-06-14 1981-02-23 Wellcome Found Pyrimidine derivatives and medicinal drug containing them
IE49992B1 (en) 1979-06-14 1986-01-22 Wellcome Found Alkoxybenzylpyridopyrimidines,methods for their preparation and pharmaceutical formulations thereof
US4959474A (en) 1979-06-14 1990-09-25 Burroughs Wellcome Co. Dialkoxy pyridopyrimidine compounds
AU598093B2 (en) 1987-02-07 1990-06-14 Wellcome Foundation Limited, The Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5426110A (en) 1993-10-06 1995-06-20 Eli Lilly And Company Pyrimidinyl-glutamic acid derivatives
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
SK281724B6 (sk) 1994-11-14 2001-07-10 Warner-Lambert Company 6-arylpyrido[2,3-d]pyrimidíny, ich použitie a farmaceutické prostriedky na ich báze
US5801183A (en) 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
DE69718306D1 (de) 1996-04-12 2003-02-13 Sumitomo Pharma Piperidinylpyrimidine derivate
KR20000070751A (ko) * 1997-02-05 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
ID24372A (id) 1997-10-27 2000-07-13 Agouron Pharma SENYAWA-SENYAWA 4-AMINO-TIAZOL-2-IL SEBAGAI PENGHAMBAT-PENGHAMBAT CDKs
KR20010043829A (ko) * 1998-05-26 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 비시클릭 피리미딘 및 비시클릭3,4-디히드로피리미딘
ES2274634T3 (es) 1998-08-29 2007-05-16 Astrazeneca Ab Compuestos de pirimidina.
DE60024631T2 (de) 1999-07-26 2006-06-14 Banyu Pharma Co Ltd Biaryl-harnstoff-derivate
CN1373763A (zh) 1999-09-15 2002-10-09 沃尼尔·朗伯公司 作为激酶抑制剂的蝶啶酮
CN1433417A (zh) * 2000-01-27 2003-07-30 沃尼尔·朗伯公司 用于治疗神经变性疾病的吡啶并嘧啶酮衍生物
BR0109056A (pt) * 2000-03-06 2003-06-03 Warner Lambert Co Inibidores da cinase de tirosina de 5-alquilpirido[2,3-d]pirimidinas
JP2004519422A (ja) * 2000-08-04 2004-07-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ２−（４−ピリジル）アミノ−６−ジアルコキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン
AU2001271611A1 (en) 2000-09-01 2002-03-22 Glaxo Group Limited Oxindole derivatives
GB0101686D0 (en) 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
CN100376571C (zh) * 2001-02-12 2008-03-26 霍夫曼-拉罗奇有限公司 6-取代的吡啶并嘧啶类化合物
DE60210819T2 (de) 2001-12-17 2007-04-19 Smithkline Beecham Corp. Pyrazolopyridazinderivate
ES2251677T3 (es) 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
JP2006503081A (ja) 2002-10-10 2006-01-26 スミスクライン ビーチャム コーポレーション 化学化合物
NZ539873A (en) 2002-11-22 2008-09-26 Smithkline Beecham Corp Novel chemical compounds, thiazolidin-4-one, thiazol-4-one
WO2004063195A1 (en) * 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
DE602004021558D1 (de) 2003-01-17 2009-07-30 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
WO2004076414A2 (en) 2003-02-27 2004-09-10 Smithkline Beecham Corporation Novel compounds
ATE412650T1 (de) 2003-07-11 2008-11-15 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
RU2009108006A (ru) 2006-09-08 2010-10-20 Пфайзер Продактс Инк. (Us) Синтез 2-(пиридин-2-иламино)-пиридо[2, 3-d]пиримидин-7-онов

Also Published As

Publication number Publication date
OA12755A (en) 2006-07-03
NO2017014I2 (no) 2017-04-19
PL391191A1 (enExample) 2005-07-11
CR20120129A (es) 2012-06-12
HK1162026A1 (en) 2012-08-17
EP1470124B1 (en) 2005-12-28
RS59804A (sr) 2006-12-15
FR17C1012I1 (enExample) 2017-07-07
CY1105686T1 (el) 2010-12-22
LTC1470124I2 (lt) 2019-04-25
NO2017014I1 (no) 2017-04-19
IL162721A (en) 2009-12-24
IL198243A (en) 2013-05-30
WO2003062236A8 (en) 2003-12-24
CN101906104B (zh) 2013-06-05
SI1470124T1 (sl) 2006-04-30
GT200300005A (es) 2003-08-22
LTPA2017013I1 (lt) 2017-05-25
CA2473026A1 (en) 2003-07-31
TNSN04126A1 (fr) 2007-03-12
AR038814A1 (es) 2005-01-26
US6936612B2 (en) 2005-08-30
DOP2003000561A (es) 2003-09-15
NO20043484L (no) 2004-10-15
NO329350B1 (no) 2010-10-04
PL220952B1 (pl) 2016-01-29
AU2003237009B2 (en) 2008-10-02
TW200302224A (en) 2003-08-01
MXPA04005939A (es) 2005-01-25
LUC00009I2 (enExample) 2017-05-30
IL162721A0 (en) 2005-11-20
SV2004001459A (es) 2004-07-07
KR20040077759A (ko) 2004-09-06
UA79444C2 (uk) 2007-06-25
IS7323A (is) 2004-06-16
EP1470124A1 (en) 2004-10-27
BRPI0307057B1 (pt) 2018-05-29
BR122016021801B8 (pt) 2021-05-25
ES2251677T3 (es) 2006-05-01
LUC00009I1 (enExample) 2017-03-16
CA2473026C (en) 2011-05-03
WO2003062236A1 (en) 2003-07-31
NL300863I2 (nl) 2017-08-03
US7208489B2 (en) 2007-04-24
HRP20040660B1 (hr) 2012-10-31
CN101906104A (zh) 2010-12-08
ZA200404840B (en) 2005-09-28
BRPI0307057B8 (pt) 2021-05-25
MEP46108A (en) 2011-02-10
KR20060111716A (ko) 2006-10-27
CN101001857A (zh) 2007-07-18
FR17C1012I2 (fr) 2018-06-08
DE60303009D1 (de) 2006-02-02
US20070179118A1 (en) 2007-08-02
MA27166A1 (fr) 2005-01-03
CY2017011I2 (el) 2017-11-14
DK1470124T3 (da) 2006-04-18
PE20030975A1 (es) 2003-11-12
US7456168B2 (en) 2008-11-25
HUS1700019I1 (hu) 2017-05-29
PL372046A1 (en) 2005-07-11
CO5700765A2 (es) 2006-11-30
CN101001857B (zh) 2011-06-22
JP2005519909A (ja) 2005-07-07
AP1767A (en) 2007-08-13
RS51044B (sr) 2010-10-31
AR083686A2 (es) 2013-03-13
BR122016021801B1 (pt) 2021-02-09
HUS1700009I1 (hu) 2017-07-28
EA200400860A1 (ru) 2004-12-30
UY27617A1 (es) 2003-08-29
KR100669578B1 (ko) 2007-01-15
NI200300008A (es) 2004-12-03
CY2017011I1 (el) 2017-11-14
DE60303009T2 (de) 2006-07-13
US20030149001A1 (en) 2003-08-07
USRE47739E1 (en) 2019-11-26
JP4291696B2 (ja) 2009-07-08
PA8563701A1 (es) 2003-09-17
CN102295643B (zh) 2013-12-04
ATE314370T1 (de) 2006-01-15
EA007395B1 (ru) 2006-10-27
US20050137214A1 (en) 2005-06-23
CN102295643A (zh) 2011-12-28
TWI343920B (en) 2011-06-21
HK1146048A1 (en) 2011-05-13
BE2017C005I2 (enExample) 2022-05-17
EA007395B3 (ru) 2018-02-28
ECSP105201A (es) 2010-02-26
ME00230B (me) 2011-02-10
HK1104296A1 (en) 2008-01-11
HN2003000039A (es) 2005-11-12
AP2004003085A0 (en) 2004-09-30
NZ534069A (en) 2007-03-30
HRP20040660A2 (en) 2004-12-31
PL218692B1 (pl) 2015-01-30
BR0307057A (pt) 2004-10-26
ECSP045201A (es) 2004-08-27
IS2423B (is) 2008-10-15
MY134818A (en) 2007-12-31

Similar Documents

Publication Publication Date Title
GEP20063909B (en) 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
AP1911A (en) Pyrrolo[2,3-d]pyrimidine compounds.
IL192337A0 (en) NOVEL 2,4,8-TRISUBSTITUTED-8h- PYRIDO[2,3-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES
AU2002246728A1 (en) Carboline derivatives
WO2002096905A8 (en) Thiazole compounds useful as inhibitors of protein kinases
WO2004076450A8 (en) Pyrazolopyridine derivates
GEP20105081B (en) Pyrrolotriazine compounds as kinase inhibitors
UA103873C2 (ru) Гетероарильные производные мочевины как ингибиторы р38 и их применение
BRPI0406809A (pt) Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
WO2004056827A3 (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
GEP20084367B (en) Diazepinoindole derivatives as kinase inhibitors
IL185611A0 (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
AU2002249890A1 (en) Carboline derivatives
IL164606A0 (en) Novel compounds
NO20052182L (no) Nye forbindelser
CA2445189A1 (en) Carboline derivatives as pdev inhibitors
CA2423357A1 (en) Fused heterocyclic derivatives as phosphodiesterase inhibitors
AU2002224431A1 (en) 2-substituted heterocyclic compounds and their use in treating multidrug resistance
WO2002067866A3 (en) Piperazine derivatives as metalloprotease inhibitors
MY145907A (en) Novel 2,4,8-trisubstitute d-8h-pyrido[2,3-d) pyrimidin-7-one compounds